# Syndax Pharmaceuticals Inc. (SNDX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.55B  
**Price:** $17.93 (+1.99%)

> Syndax Pharmaceuticals Inc. is a commercial stage oncology innovator focused on developing cancer therapies for areas of significant unmet medical need. The company's product portfolio includes Revuforj, a menin inhibitor approved for treating relapsed or refractory NPM1-mutated acute myeloid leukemia in adult and pediatric patients, along with Niktimvo, an axatilimab-based therapeutic. The company also operates proprietary platforms including SyndAccess and IncyteCARES, which support its drug development and patient care initiatives. Syndax Pharmaceuticals targets oncologists and patients dealing with acute leukemias and related hematologic malignancies, positioning itself within the biotechnology sector as a specialized pharmaceutical developer addressing critical gaps in cancer treatment. Founded in 2005 and headquartered in New York, the company combines research-stage development capabilities with commercial product distribution to serve the global oncology market.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $172M | — | -$273M | -$285M | — |
| 2024 | $24M | — | -$340M | -$319M | — |
| 2023 | — | — | -$230M | -$209M | — |
| 2022 | — | — | -$152M | -$149M | — |
| 2021 | $140M | — | $26M | $25M | — |
| 2020 | $2M | — | -$71M | -$73M | — |
| 2019 | $2M | — | -$58M | -$56M | — |
| 2018 | $2M | — | -$76M | -$74M | — |
| 2017 | $2M | — | -$62M | -$61M | — |
| 2016 | $1M | — | -$44M | -$44M | — |
| 2015 | $627,000 | — | -$21M | -$24M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $530M | $465M | $65M | $135M | — |
| 2024 | $725M | $437M | $288M | $154M | — |
| 2023 | $613M | $59M | $554M | $295M | — |
| 2022 | $497M | $30M | $467M | $74M | — |
| 2021 | $450M | $41M | $408M | $222M | — |
| 2020 | $301M | $48M | $252M | $115M | — |
| 2019 | $64M | $32M | $32M | $25M | — |
| 2018 | $84M | $31M | $53M | $34M | — |
| 2017 | $137M | $33M | $104M | $35M | — |
| 2016 | $109M | $25M | $84M | $24M | — |
| 2015 | $90M | $23M | -$252M | $23M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$323M | $187,000 | -$323M |
| 2024 | -$275M | — | -$275M |
| 2023 | -$161M | — | -$161M |
| 2022 | -$134M | — | -$134M |
| 2021 | $29M | $129,000 | $29M |
| 2020 | -$71M | — | -$71M |
| 2019 | -$51M | — | — |
| 2018 | -$69M | $187,000 | -$69M |
| 2017 | -$47M | $84,000 | -$47M |
| 2016 | -$35M | $261,000 | -$35M |

Source: [CompaniesByCap](https://companiesbycap.com/company/SNDX)